Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | PDE5A | O76074 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13676637 | 0.84 | HTT (0.57) | RECQLMAOAMAOBSMN1; SMN2PDE5A | |
| SCHEMBL20119459 | 0.84 | RECQL (0.51) | RECQLJAK2MAOAMAOBSMN1; SMN2 | |
| SCHEMBL5997041 | 0.82 | CDK1 (0.48) | JAK2LMNATSHRKMT2AMEN1 | |
| SCHEMBL3298449 | 0.82 | CDK2 (0.40) | RECQLMAOAMAOBSMN1; SMN2NPC1 | |
| SCHEMBL30850618 | 0.80 | RECQL (0.65) | RECQLMAOAMAOBSMN1; SMN2PDE5A | |
| SCHEMBL15426196 | 0.80 | RECQL (0.65) | RECQLMAOAMAOBSMN1; SMN2PDE5A | |
| SCHEMBL3302940 | 0.79 | IGF1R (0.43) | MAOAMAOBLMNAALDH1A1KMT2A | |
| SCHEMBL3304345 | 0.78 | KCNH3 (0.39) | JAK2SMN1; SMN2PDE5AHTTLMNA | |
| SCHEMBL17450144 | 0.78 | AURKA (0.41) | JAK2SMN1; SMN2HTTLMNATSHR | |
| SCHEMBL17442983 | 0.78 | LMNA (0.52) | PDE5AHTTLMNAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612079-B2 | 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-20090270427-A1 | PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270427-A1 | PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270427-A1 | PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-7544689-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-7544689-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-7544689-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| CN-1312152-C | Novel purine derivatives | CYCLACEL LTD (GB) | 2007-04-25 | — | — | CN | disclosed |
| US-20060183760-A1 | New purine derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-08-17 | — | — | US | disclosed |
| EP-1534708-B1 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | CYCLACEL LTD (GB) | 2006-04-26 | — | — | EP | disclosed |
| US-20050256142-A1 | 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-11-17 | — | — | US | disclosed |
| CN-1675213-A | Novel purine derivatives | CYCLACEL LTD (GB) | 2005-09-28 | — | — | CN | disclosed |
| EP-1399446-B1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LTD (GB) | 2005-08-03 | — | — | EP | disclosed |
| EP-1534708-A2 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | Cyclacel Limited (GB) | 2005-06-01 | — | — | EP | disclosed |
| US-20050009846-A1 | 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-01-13 | — | — | US | disclosed |
| EP-1399446-A1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2004016613-A2 | PURINE DERIVATIVES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | CYCLACEL LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
| WO-2003002565-A1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE N THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183760-A1 | New purine derivatives | C5, CYC1, CCNH | RECQL 565/4885JAK2 904/4885MAOA 1770/4885 |
| US-20050256142-A1 | 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors | CDK1, CDK2, CCND1 | RECQL 1051/4885JAK2 55/4885MAOA 2371/4885 |
| US-20050009846-A1 | 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders | TYMP, PNP, IMPDH1 | RECQL 206/4885JAK2 250/4885MAOA 3267/4885 |
| US-20090270427-A1 | PURINE DERIVATIVES | C5, CYC1, CCNH | RECQL 584/4885JAK2 668/4885MAOA 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.